Skip to main content

Advertisement

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Fig. 5

The effect of gemcitabine on effector lymphocytes. Ten pancreatic cancer patients were sampled during the first cycle of gemcitabine treatment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 1, 8, 15 and 29 always before gemcitabine was given that day. Patient and healthy control (HC) samples were stained for CD3+ lymphocytes, CD4+ and CD4 T cells (CD8+) and NK cells (CD56+CD16+). T cell activation was assessed by CD107a expression and the samples were analyzed by flow cytometry. Statistical differences between HCs and patients or between sample days were assessed by unpaired t-test with Welch’s correction or Wilcoxon matched-pairs signed-rank test, respectively (*P < 0.05, ****P < 0.0001)

Back to article page